People who have had a stroke are at increased risk of further occlusive vascular events, such as recurrent stroke or myocardial infarction. For people who have had a non‑cardioembolic ischaemic stroke ...
Pilot Programme Study Results underpinning NHS Implementation Guide for CYP2C19 Genotype Testing Presented at the UK Stroke Forum genedrive plc (AIM: GDR), the point of care pharmacogenetic testing ...
NICE has said that CYP2C19 genotype testing can be used to assess whether clopidogrel is a suitable antiplatelet drug for people who have had an ischaemic stroke or a transient ischaemic attack (TIA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback